Investing & Partnering Conference

NEUROTECHEUROPEAN4th

INTERNATIONAL 3 - 4 OCTOBER 2017

THE WYSS CENTER AT CAMPUS BIOTECH | GENEVA, SWITZERLAND

NeurotechPartneringEurope.comA Division of Cambridge Innovation Institute

CambridgeHealthtech InstituteOrganized by

PARTNERS

Final Weeks to Register! Join us in Geneva

KEYNOTE PRESENTATIONS

Towards a Major Service-Based Research Infrastructure for Brain ResearchChristoph Ebell, Executive Director, Human Brain Project

From Concept to Clinic: Neurotechnology Translation TodayJohn Donoghue, Ph.D., Founding Director, Wyss Center for Bio and Neuroengineering

Endeavour Vision • FutuRx Ltd. • J&J Development Corporation • Medtronic Merck Ventures • Mitsubishi • Tanabe Holdings America, Inc. • NIO

Novartis • Soffinova • UCB Pharma

Join neurotech executives, investors and partners and key deal makers from:

NeuroInsightswww.neuroinsights.com

For over a decade, NeuroInsights has been helping entrepreneurs, executives,

investors, and governments understand and profit from the growth of drugs, devices and diagnostics for the brain and nervous system. We achieve this through a broad range of strategic business advisory services, in-depth market and industry investment reports, Neurotech Insights - our monthly industry newsletter covering financing and product news, and our flagship neurotech investing and partnering conferences. NeuroInsights will enable you to track market dynamics, develop investment strategies, identify partnering opportunities, and analyze comparables across this $160 billion global industry.

Neurotechnology Industry Organization (NIO)www.neurotechindustry.org

Since 2006, over 120 neuroscience organizations have joined the Neurotechnology Industry Organization in our mission to accelerate neurotechnology research,

development and commercialization, including neuroscience companies, brain research institutes, and patient advocacy groups across the spectrum of neurological disease, psychiatric illnesses and nervous system injuries. NIO’s programs have the following goals: advocate the industry’s position to regulators and elected officials; inform the media about industry’s progress and contributions to quality of life; provide industry events and business development services to the industry; foster leadership positions that drive innovation forward.

Cambridge Healthtech Institutewww.healthtech.com

Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top

pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, Next Generation Dx Summit and Discovery on Target. CHI’s portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Knowledge Foundation, Bio-IT World, Clinical Informatics News and Diagnostics World.

The neurotechnology industry is delivering innovative therapeutics and devices to more effectively treat CNS disorders, a significant unmet medical need that is only increasing with an aging population, better screening and more awareness.

Strategic partnerships continue to drive neurotech forward, facilitating breakthroughs, enabling commercialization, and easing adoption.

The Fourth International Neurotech Investing and Partnering Conference Europe is a must-attend partnering and investing conference for the neurotechnology industry:

• DELEGATES: investors, executives, entrepreneurs, scientists

• FORMAT: 1:1 meetings, facilitated networking, industry overviews, company presentations, panel discussions

• APPLICATIONS: pharmaceuticals, medical devices, software, diagnostics, clinical trials

• RESEARCH: Alzheimer’s, dementias, Parkinson’s, movement disorders, next-gen psychiatry

• OPPORTUNITIES: R&D collaborations, strategic alliances, partnering, licensing, investing

• FOCUS: emerging companies, trends, requirements, de-risking, business models, valuation, deals

We are excited to partner with the Wyss Center for an event that promises to provide an ideal venue to connect investors with potential partners, and launch the new relationships that will grow into tomorrow’s successful treatments and partnerships.

We hope to see you in Geneva!

Alison Fenney, MBA, Ph.D. Executive Director Neurotechnology Industry Organization (NIO)

Welcome

2 | NeurotechPartneringEurope.com

PARTNERS

Investing & Partnering ConferenceNEUROTECHEUROPEAN4th INTERNATIONAL

3 - 4 OCTOBER 2017

THE WYSS CENTER AT CAMPUS BIOTECH | GENEVA, SWITZERLAND

Organized by

3 |NeuroTechPartnering Europe.com

TUESDAY, 3 OCTOBER

7:30 Conference Registration and Continental Breakfast

8:30 Welcome and State of the Industry Keynote Alison Fenney, Executive Director, Neurotechnology Industry Organization

KEYNOTE PRESENTATION: From Concept to Clinic: Neurotechnology Translation Today John Donoghue, Ph.D., Founding Director, Wyss Center for Bio and Neuroengineering

9:00 Investing in Neurotech Panel Discussion A diverse panel of private, public and strategic investors will discuss what it takes to get a neurotech company funded. The benefits and risks of

business models in devices, pharmaceuticals, diagnostics and information technology will be addressed. Delegates will learn more about today’s deal terms and valuations as well as exit strategies. Finally, the neurotech industry will be evaluated in comparison with other industries.Moderator: John B. Reppas, M.D., Ph.D., Director of Public Policy, Neurotechnology Industry OrganizationPanelists:Daniel Bertholet, Senior Investment Director, Endeavour VisionJasper Bos, Ph.D., Vice President, Head, Healthcare Fund, Merck VenturesYaron Breski, MBA, Managing Director, RM Global PartnersFrancesco De Rubertis, Partner, Medicxi

10:00 Coffee Break with Exhibit Viewing

10:45 Treatment for Alzheimer’s and Cognitive Disorders Alzheimer’s disease and related dementias affect over 46 million people worldwide, with an estimated cost of $818 billion. Ongoing efforts to

develop disease modifying therapies have been plagued with failures. This session will address new avenues being pursued to address the growing global need, novel diagnostics for early detection, and non-pharmacological options in development.

Moderator:DanielO’Connell,MBA,Foundingmember&ManagingPartner,NeuroVentures;PresidentandChiefExecutiveOfficer,AcumenPharmaceuticals, Inc.

Alzheon, Inc. – A Precision Medicine Approach to Alzheimer’s Disease Martin Tolar, M.D., Ph.D., Founder, President & CEO, Alzheon, Inc.

O-Glcnacase Inhibitor ASN120290 as Anti-Tau Drug Candidate for Alzheimer’s Disease and Other Tauopathies Dirk Beher, Ph.D., CEO, Asceneuron SA

ORY-2001 an Epigenetic Inhibitor Targeting LSD1 is a Therapeutic Candidate to Treat Alzheimer’s Disease and Other Neurodegenerative Disorders

Carlos Buesa, CEO, Oryzon

12:15 pm Networking Luncheon

14:15 Panel Discussion: Internal and External R&D Panel Discussion Big pharma, medtech, and biotech companies collaborate with smaller companies and academic institutions on a variety of projects. This panel

discussion will address opportunities for research and development collaborations with academic groups, research institutes, and platform companies. Delegates will learn how to spot opportunities, current areas of interest, and how to focus internal and external resources.Moderator: John B. Reppas, M.D., Ph.D., Director of Public Policy, Neurotechnology Industry OrganizationPanelists: Jeff Erb, Senior Director, Strategy, Business Development and Alliance Management, MedtronicPierandrea Muglia, Vice President, Neuroscience Discovery, UCB Pharma

15:15 Refreshment Break with Exhibit Viewing

16:00 Frontiers in Neurotechnology This session includes companies on the cutting edge of neuroscience. Novel neurostimulation devices for a variety of indications, software solutions

for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Companies in this session will showcase their innovative next-generation products and how they are addressing unmet needs in neurotech.Moderator: Sharon Fan, Advisor, Triomi Medical Innovations

Combining Functional Imaging with Neuromodulation AnnBunnenberg,Ph.D.,JD,ChiefOperatingOfficerandPresident,ElectricalGeodesics,Inc.

Talk Title to be AnnouncedSusan Rosenbaum, J. D., CEO, Founder, Chairman, Lauren Sciences LLC

How to Revolutionize Treatments for Brain Cancer and Neurologic Conditions Frederic Sottelini, CEO, CarThera

NeurotechPartneringEurope.com | 4

TUESDAY, 3 OCTOBER

17:00 Emerging Company Showcase This showcase allows neurotechnology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and

executives in the field. Companies presenting in this session are addressing unmet medical needs, were founded no earlier than 2012, and are actively seeking funding.

Moderator: Alison Fenney, Executive Director, Neurotechnology Industry Organization Participants: Thomas de Vlaam, CEO, Amylon Therapeutics Haritz Zabaleta Rekondo, CTO, Fesia Technology S.L. EfiCohenArazi,Director,BrainBalance Goran Bijelic, CEO, Elcode Jean-René Bélanger, CEO, Imeka

17:30 Welcome Reception with Exhibit Viewing

18:30 Close of Day

8:00 Conference Registration and Continental Breakfast

8:30 KEYNOTE PRESENTATION: Towards a Major Service-Based Research Infrastructure for Brain Research Christoph Ebell, Executive Director, Human Brain Project

9:30 Coffee Break with Exhibit Viewing

10:15 Bench to Bedside, Profiling the Wyss Center Panel Discussion This session will feature discussions around the funding and de-risking of early neurotech concepts, offer advice on how to attract investors, and

give tips on how to avoid common pitfalls on the journey of a new concept from lab bench to the clinic. Moderator: Tracy Laabs, Ph.D., Assistant Director, Wyss Center Panelists: Claude Clément, CTO, Wyss Center DanielO’Connell,MBA,Foundingmember&ManagingPartner,NeuroVentures;PresidentandChiefExecutiveOfficer,AcumenPharmaceuticals,Inc. Joern Rickert, Ph.D., CEO, CorTec GmbH Claudio Pollo, M.D., Head, Functional Neurosurgery, University Hospital Berne, Switzerland

11:15 Panel Discussion: Partnering and Licensing in Neurotech Neurology is projected to be medtech’s fastest-growing segment in the next five years. Pharma companies are adapting to the current environment

with targeted deal-making. This panel will address current trends in strategic alliances and inlicensing, priority indications and requirements for licensing deals, and companies active in deal-making.Moderator: David A. Lowe Ph.D., Co-Founder & CEO, NeuroAssets Panelists:Maciek Drozdz, Principal, Venture Investments, J&J Development CorporationCharlie Bailey, Ph.D., Global Head, Neuroscience, Business Development & Licensing, Novartis Patrik Frei, Ph.D., CEO, Venture ValuationAlexander Breidenbach, MBA, Global Head, Neuroscience Partnering, F. Hoffmann La Roche Ltd.Catherine Abbadie, Ph.D., Senior Director, Business Development, Sunovion Pharmaceuticals Inc

12:15 pm Networking Luncheon

13:45 Next Generation Psychiatry Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a substantial portion of the neurotech market. This

session will focus on the most promising next-generation treatments as well as devices and diagnostics to change the treatment landscape.

RP5063, a Novel Dopamine-Serotonin Stabilizer for Treating Schizophrenia and Schizoaffective Disorders Laxminarayan Bhat, Founder, President & CEO, Reviva Pharmaceuticals Inc.

Talk Title to be Announced Jean-Yves Quentel, CEO Mensia Technologies

14:45 Strategies in CNS Drug Development (Sponsorship Opportunities Available) Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech

venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement. Moderator: Carla M. Lema Tome, MBA, Ph.D., INC Research Panelists: David Ewbank, Partner, Executive Insights Carla M. Lema Tome, MBA, Ph.D., INC Research Joseph Araujo, President and CEO, Intervivo

15:45 Networking Refreshment Break

WEDNESDAY, 4 OCTOBER

WEDNESDAY, 4 OCTOBER

16:00 Parkinson’s and Other Movement Disorders Current treatments for movement disorders can improve functioning but suffer from side effects and “off” period especially as the disease

progresses. In this session, speakers will share the latest advances in movement disorders including how to address side effects, disease modifying treatments, and the role of diagnostics in improving outcomes.

Achieve Immunotherapy Candidates PD01A, PD03A Targeting Alpha Synuclein in Parkinson´s Patients Oliver Siegel, CEO, AFFiRiS AG

Partnering in Parkinson’s Disease and Movement Disorders from Pharma’s Perspective Atsushi Hashimoto, Director, Business Development, Mitsubishi Tanabe Holdings America, Inc.

Opening New Therapeutic Options Against Multiple Sclerosis and Other Autoimmune Diseases Jesús Martin-Garcia, Chairman and CEO, GeNeuro

A New Drug Discovery Paradigm Pioneered by Pharnext: PLEOTHERAPYTM XavierPaoli,ChiefCommercialOfficer;VPR&DOperations,Pharnext

Talk Title to be Announced Michael Almstetter, CEO, Origenis GmbH

17:00 Close of Conference

How to Register: NeuroTechPartneringEurope.comreg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode CNPE F

when registering!

EVENT PRICING Academic, Government, Hospital-affiliated Commercial NIOMembers

Registrations after 22 September 2017, and on-site €2069 €2379 €1909

EVENTDISCOUNTS

REGISTER 3 - 4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.GroupDiscountsAvailable: Special rates are available for multiple attendees from the same organization. For more information on group and government discounts contact Bill Mote at 781-972-5479

ADDITIONAL REGISTRATIONDETAILSEach registration includes all con-ference sessions and exhibits, food functions, and access to the conference partnering software.

Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.ToviewourSubstitutions/Cancellations Policy, go to healthtech.com/regdetailsVideo and or audio recording of any kind is prohibited onsite at all CHI events.

PRICING AND REGISTRATION INFORMATION

NeurotechPartneringEurope.com | 5

SPONSORSHIP & EXHIBIT INFORMATION

Promotion of the 4th Annual Event and its SponsorsOutreach and marketing will be conducted regularly from February 2017 to October 2017 including at other events, via mail and email and social media. • Direct marketing efforts including mailers and email highlighting the

conference and its sponsors are targeted to opt in lists of 20,000 people. • The Neurotechnology Industry Organization will be promoting the

conference and its sponsors in collaboration with NeuroInsights at conferences throughout the fall, winter and spring.

• Promoted in email alerts for Neurotech Insights that reaches over 18,000 people monthly

• Promotion in collaboration with partner organizations including Biospace, Genetic Engineering & Biotechnology News and The Scientist and others.

Why Sponsor at the Neurotech Europe 2017?The Neurotech Europe 2017 conference provides a best opportunity for exhibitors to promote their products, services and publications to leading decision makers, executives, and scientists in commercial neuroscience. • Establish new customer leads• Demonstrate products/services to a diverse group of leading companies• Maintain a market presence• Gain recognition with emerging neuropharma companies, key specialty

companies, investors, big pharma, major medical device companies and the media

Premier Sponsor/Presentation $25,000 • 15-minute presentation to all session attendees as part of the main

conference program or relevant panel• Eight (8) main conference registrations including speaker• 1 copy of The Neurotechnology Industry 2016-2017 Report• Sponsor logo will be highlighted as sponsoring lunch or cocktail hour• Distribution of marketing materials to attendees at a display table• Sponsor will create an advertising page for conference booklet• One 2m x 1m exhibit space • Corporate logo inside the final conference brochure PDF• Additional full conference registrations available at a discount for your staff

(Limited to 5)• Corporate logo with link on the event website• 50-word company description in the Program & Exhibits Guide• On-site signage designating your company as a corporate sponsor• One-time use of delegate list – for one pre and one post-show physical mailing • Cooperative promotional email to your list of customers/prospects

promoting your presence at the event and offering them a discount to attend

Corporate Sponsor $20,000 • Six (6) main conference registrations• 1 copy of The Neurotechnology Industry 2016-2017 Report• Sponsor logo will be highlighted as sponsoring lunch or cocktail hour• Distribution of marketing materials to attendees at a display table• Sponsor will create an advertising page for conference booklet• One 2m x 1m exhibit space • Corporate logo inside the final conference brochure PDF• Additional full conference registrations available at a discount for your staff

(Limited to 5)• Corporate logo with link on the event website• 50-word company description in the Program & Exhibits Guide• On-site signage designating your company as a corporate sponsor• One-time use of delegate list – for one pre and one post-show physical mailing • Cooperative promotional email to your list of customers/prospects

promoting your presence at the event and offering them a discount to attend

Corporate Support Sponsor $10,000 • Four (4) main conference registrations• Sponsor logo will be highlighted as sponsoring lunch or cocktail hour• Distribution of marketing materials to attendees at a display table• Sponsor will create an advertising page for conference booklet• One 2m x 1m exhibit space • Corporate logo inside the final conference brochure PDF• Additional full conference registrations available at a discount for your staff

(Limited to 5)• Corporate logo with link on the event website• 50-word company description in the Program & Exhibits Guide• On-site signage designating your company as a corporate sponsor• One-time use of delegate list – for one pre and one post-show physical mailing • Cooperative promotional email to your list of customers/prospects

promoting your presence at the event and offering them a discount to attend

Standard Rate for Full Booth Area (2m x 1m) $4,195

ACT NOW – Limited Exhibit Availability!

For more information regarding sponsorship and exhibit opportunities, please contact:Rod Eymael

Manager, Business Development (+1) 781-247-6286

reymael@healthtech.com

HOTEL & TRAVEL INFORMATION

Conference Venue: The Wyss Center at Campus BiotechChemin des Mines 9CH-1202 Geneva, Switzerlandwww.wysscenter.ch/www.campusbiotech.ch/

Host Hotel: Hôtel N’vYRue de Richemont 181201 Geneva, SwitzerlandPhone: +41 (0) 22 544 66 66

Reservations: Go to the hotel and venue page of NeurotechPartneringEurope.com

Discounted Room Rate: CHF 280/s 310/d (includes complimentary Wi-Fi and Buffet Breakfast)Discounted Cut-off Date: 31 August 2017

NeurotechPartneringEurope.com | 6

1 |NeuroTechPartnering Europe.com

Final Weeks to Register! Join us in Geneva

■ Pharma/Biotech 38%■ Devices 13%■ Research Institute 12%■ Investors10%■ Diagnostics 9%■ CRO 8%■ Consultant 5%■ Other 5%

COMPANY TYPE

ATTENDEE DEMOGRAPHICS

■ C-Level Executives 39%■ Director 18%■ VP 13%■ Business Development 8%■ Manager 8%■ Other 7%■ Professor 4%■ Scientist 3%

DELEGATE TITLE

AAT RESEARCH LTD.ABC & D (on behalf of Crossbeta)

Action Potential Venture Capital

Addex Pharma S.A.AFFiRiS AGAlcobraAllinky BiopharmaAmarantus BioScience Holdings

AsceneuronBioAlps AssociationBioArctic NeuroscienceBlue Brain Project EPFLCambridge Cognition Ltd.CavionCennerv Pharma (S) Pte Ltd.Cerecor, Inc.Clinical Trial Centers AllianceCollaborative Neuroscience Network

CorTec GmbHCortexymeCorundum Open InnovationDesitin Arzneimittel GMBHDonders Institute, Radboud University

Duke University

Electrical Geodesics, Inc. (EGI)Endeavour VisionEPFL / Brain Mind InstituteHAPPYneuronHasbro Children’s HospitalHigh-Tech GründerfondsHiQScreenHoffman-LaRocheINC Researchinstitut de recherches ServierJ&J InnovationJunaxoKetogenLund UniversityMedtronicMindMaze SAMinerva NeurosciencesMS VentursN2MONestlé Institute of Health Sciences SA

NeurabNeuroAssetsNeurocrine BiosciencesNEUROELECTRICSNeuroInsightsNeuroscience Trials AustraliaNeurotar Ltd.Neurotechnology Industry

Organization (NIO)Nexstim OyjnLife Therapeutics, S.L.Novartis PharmaceuticalsNovo A/SNsGene, Inc.Ontario Brain InstitutePear Therapeutics, Inc.PfizerPhotoPharmics, Inc.Piramal Imaging GmbHPPDProbiodrug AGQbtech Ltd.SanionaSelonterraSofinnova PartnersSomno-Art/PPRSSpot-On TherapeuticsSumitomo Dainippon PharmaSwiss Biotech AssociationSynAgingTakeda PharmaceuticalsTeijin Pharma Ltd.Teva PharmaceuticalsUCB PharmaUniversity of HelsinkiWyss Center for Bio and Neuroengineering

Past Attendees Include

PARTNERS

A Division of Cambridge Innovation Institute

CambridgeHealthtech InstituteOrganized by

NeurotechPartneringEurope.com

DISCOVER PARTNERING

OPPORTUNITIES from Across Commercial

Neuroscience

Make the high quality relationships that are key to the success of your venture

EXPAND YOUR NEURO NETWORK IN EUROPE■ Don’t miss a unique opportunity to explore 1:1 partnering at a targeted, neuro-focused event.

■ Discover promising leads and develop strategic relationships with our online partnering tool.

■ Search for companies and set up a profile so potential partners can find you.

■ Manage your contacts and schedule before, during and after the event.

WHAT YOU CAN EXPECT IN GENEVA*

460+ MEETING REQUESTS

175+ CONFIRMED MEETINGS

*metrics taken from 2017 US event

65% of conference attendees used the online partnering tool to conduct onsite meetings